This paper is in the following e-collection/theme issue:

Breast Cancer (260) Mobile Health (mhealth) (3283) Patient-Reported Outcome Measures (PROMs) (338) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1631) Innovations and Technology in Cancer Care (485) Cancer Self-Management (76)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54178, first published .
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Authors of this article:

Andreas Trojan1, 2 Author Orcid Image ;   Sven Roth3 Author Orcid Image ;   Ziad Atassi2 Author Orcid Image ;   Michael Kiessling2 Author Orcid Image ;   Reinhard Zenhaeusern4 Author Orcid Image ;   Yannick Kadvany5 Author Orcid Image ;   Johannes Schumacher6 Author Orcid Image ;   Gerd A Kullak-Ublick1 Author Orcid Image ;   Matti Aapro7 Author Orcid Image ;   Alexandru Eniu8 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

Journals

  1. Liu W, Niu J, Huo Y, Zhang L, Han L, Zhang N, Yang M. Role of circular RNAs in cancer therapy resistance. Molecular Cancer 2025;24(1) View
  2. Asper N, Witschel H, von Stockar L, Laurenzi E, Kolberg H, Vetter M, Roth S, Kullak-Ublick G, Trojan A. Using Machine Learning Approaches on Dynamic Patient-Reported Outcomes to Cluster Cancer Treatment-Related Symptoms. Current Oncology 2025;32(6):334 View